News from adamas pharmaceuticals, inc

Jun 16, 2014, 16:01 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP...

Jun 10, 2014, 08:31 ET

Adamas Pharmaceuticals Announces Rater Training Data on ADS-5102 for Parkinson's Disease Patients with Levodopa-Induced Dyskinesia

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today presented data on the rater and subject training process utilized in the Phase 2/3 EASED...

Jun 09, 2014, 16:01 ET

United States Patent Issued To Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No....

Jun 09, 2014, 16:01 ET

Adamas Pharmaceuticals Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has initiated a pivotal Phase 3 clinical study of ADS-5102 (amantadine HCl), a...

May 29, 2014, 16:05 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Pharmaceuticals Announces Data Update At The International Congress Of Parkinson's Disease And Movement Disorders

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced a poster presentation at the 18th International Congress of Parkinson's Disease...

May 20, 2014, 16:05 ET

Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings...

May 13, 2014, 16:00 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Reports First Quarter 2014 Financial Results

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the quarter ended March 31, 2014. "During the first quarter we...

Apr 30, 2014, 11:25 ET

Adamas Pharmaceuticals proporciona una actualización de datos sobre el fármaco ADS-5102 en la reunión anual de la Academia Americana de Neurología

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), una compañía farmacéutica de especialidades, presentó hoy datos sobre la eficacia...

Apr 30, 2014, 09:00 ET

Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for...

Apr 23, 2014, 16:00 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting

 Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy...

Apr 15, 2014, 16:00 ET

Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering

 Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial...

Apr 09, 2014, 18:55 ET

Adamas Pharmaceuticals Announces Pricing Of Its Initial Public Offering

Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000...

Jan 09, 2014, 09:00 ET

Adamas Pharmaceuticals gana $40 millones en pagos por cumplimiento de hitos de Forest Laboratories para MDX-8704

Adamas Pharmaceuticals, Inc. hoy anunció que ha recibido $40 millones en pagos por cumplimiento de hitos de Forest Laboratories Holdings...

Jan 09, 2014, 09:00 ET

Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704

 Adamas Pharmaceuticals, Inc. announced today that it has received $40 million in milestone payments from Forest Laboratories Holdings Limited...

Oct 02, 2013, 11:30 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson

- Los resultados de la prueba EASED fase 2/3 demuestran un incremento de aproximadamente tres horas de período de respuesta a los medicamentos...

Oct 02, 2013, 11:30 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinson's Congress

Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED™ clinical trial of ADS-5102 at the World Parkinson's...

Jun 18, 2013, 08:00 ET
Adamas Pharmaceuticals, Inc.  (PRNewsFoto/Adamas Pharmaceuticals, Inc.)

Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease

Adamas Pharmaceuticals, Inc. presented final results today from a Phase 2/3 clinical trial of ADS-5102 (amantadine HCl extended release) capsules...

Jun 10, 2013, 08:00 ET

Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinson's Disease

Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED™ (Extended Release Amantadine Safety and Efficacy Study in...

Apr 22, 2013, 08:30 ET

Adamas Pharmaceuticals Announces Issuance of First US Patent for Nurelin™ (Amantadine HCl Extended Release) Program

 Adamas Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,389,578...

Mar 20, 2013, 07:00 ET

Adamas Pharmaceuticals Presents New Traumatic Brain Injury Data From Its Nurelin™ Program At American Academy Of Neurology Conference

EMERYVILLE, Calif., March 20, 2013 /PRNewswire/-- Adamas Pharmaceuticals, Inc. will present research results today from its NurelinTM...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge